<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01237171</url>
  </required_header>
  <id_info>
    <org_study_id>Cs131-Lung001</org_study_id>
    <nct_id>NCT01237171</nct_id>
  </id_info>
  <brief_title>A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer</brief_title>
  <official_title>Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IsoRay Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IsoRay Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients diagnosed with early (Stage I) non-small cell lung cancer, a lobe of lung is&#xD;
      usually removed at surgery to treat the cancer. For some patients, the removal of a lobe of&#xD;
      lung may leave too little lung behind for easy breathing. For some of these patients, it may&#xD;
      be possible to perform a smaller-scale surgery (&quot;sub-lobar resection&quot;) and place a&#xD;
      radioactive implant behind to prevent the cancer from growing back. This study will see how&#xD;
      these patients do in terms of controlling their disease treated with a radioactive implant&#xD;
      called Cesium-131.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never moved past ideation phase&#xD;
  </why_stopped>
  <start_date type="Anticipated">November 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Local Recurrence</measure>
    <time_frame>3 Years</time_frame>
    <description>Cancer regrowth in the area where it was surgically removed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Using questionnaires, data will be collected related to the sense of well-being experienced by the patient after treatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>NSCLC</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Sub-lobar resection with Cesium-131</arm_group_label>
    <description>All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cesium-131 Brachytherapy Seed</intervention_name>
    <description>85 Gray Dose</description>
    <arm_group_label>Sub-lobar resection with Cesium-131</arm_group_label>
    <other_name>Sealed Brachytherapy Source CS-1 (IsoRay Medical)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with clinical stage I non-small cell lung cancer who are not candidates for full&#xD;
        lobectomy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have suspicious lung nodule for clinical stage I/recurrent non-small&#xD;
             cell Lung Cancer&#xD;
&#xD;
          2. Mass Tumor size &lt; 7 cm&#xD;
&#xD;
          3. Patient must have a CT scan of the chest with upper abdomen within 90 days prior to&#xD;
             date of pre-registration.&#xD;
&#xD;
          4. Patient must have ECOG/Zubrod performance status 0,1, or 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has already received high dose radiation to the area&#xD;
&#xD;
          2. Cancerous nodule is very close to the esophagus or spinal cord, thereby increasing the&#xD;
             risk of radiation treatment&#xD;
&#xD;
          3. Pregnancy or unwillingness to practice a form of birth control (i.e. abstinence, oral&#xD;
             contraceptives, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhupesh Parashar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 5, 2010</study_first_submitted>
  <study_first_submitted_qc>November 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brachytherapy</keyword>
  <keyword>Lung Brachytherapy</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Sub-lobar resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

